Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.74 |
| ▸ | GAA | P10253 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5827968 | 0.93 | HTR2A (0.80) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL7164084 | 0.89 | HTR2A (0.64) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4112112 | 0.89 | HTR2A (0.74) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL12524469 | 0.89 | HTR2A (0.74) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL14621621 | 0.89 | HTR2A (0.74) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL30679539 | 0.88 | HTR2A (0.62) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| Water SCHEMBL10938437 | 0.88 | HTR2A (0.73) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| Water SCHEMBL10938430 | 0.88 | HTR2A (0.73) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL14498824 | 0.87 | HTR2A (0.57) | HTR2AGAAALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4438090 | 0.87 | GAA (0.65) | HTR2AGAAALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208421-B2 | 2-carboxypenam compound or salt thereof, pharmaceutical composition containing novel 2-carboxypenam compound or salt thereof, and applications thereof | FUJIFILM CORPORATION (JP) | 2021-12-28 | — | — | US | disclosed |
| US-20200239495-A1 | NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, AND APPLICATIONS THEREOF | FUJIFILM CORPORATION (JP) | 2020-07-30 | — | — | US | disclosed |
| WO-2019070052-A1 | NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAID COMPOUND OR SALT, AND APPLICATION THEREOF | 富士フイルム株式会社 | 2019-04-11 | — | — | WO | disclosed |
| US-9511064-B2 | Combination therapy for the treatment of cancer and immunosuppression | BASILEA PHARMACEUTICA AG (CH) | 2016-12-06 | — | — | US | disclosed |
| US-20150157622-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | BASILEA PHARMACEUTICA AG (CH) | 2015-06-11 | — | — | US | disclosed |
| EP-2872505-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | Basilea Pharmaceutica AG (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014009222-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | BASILEA PHARMACEUTICA AG (CH) | 2014-01-16 | — | — | WO | disclosed |
| US-7183282-B2 | Substituted heterocycle fused γ-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-11-04 | — | — | US | disclosed |
| EP-1019378-B1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6541497-B1 | Amino acid derivatives of benzoxazin-2-ylaminoalkoxyphenylalkyl compounds | ELI LILLY AND COMPANY | 2003-04-01 | — | — | US | disclosed |
| US-6353027-B1 | ENANTIOMORPHIC AMINE DERIVATIVES FOR TREATMENT OF DIABETES | ELI LILLY AND COMPANY | 2002-03-05 | — | — | US | disclosed |
| EP-1019378-A4 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2001-09-26 | — | — | EP | disclosed |
| US-6194446-B1 | NON-INSULIN DEPENDENT DIABETES | ELI LILLY AND COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-0925063-A4 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | LILLY CO ELI (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6121282-A | 3-(CARBOXY, AMIDO, CYANO, OR HYDROXYAMINOCARBONYL)-6 OR 7-SUBSTITUTED-1,2,3,4-TETRAHYDROISOQUINOLINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-1019378-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0925063-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-06-30 | — | — | EP | disclosed |
| WO-1998000137-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1998000403-A1 | HYPOGLYCEMIC AND HYPOLIPIDEMIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208421-B2 | 2-carboxypenam compound or salt thereof, pharmaceutical composition containing novel 2-carboxypenam compound or salt thereof, and applications thereof | CFTR, SLC11A2, SLC20A1 | HTR2A 4575/4885GAA 1934/4885ALDH1A1 2623/4885 |
| US-20200239495-A1 | NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING NOVEL 2-CARBOXYPENAM COMPOUND OR SALT THEREOF, AND APPLICATIONS THEREOF | CFTR, SLC11A2, SLC20A1 | HTR2A 4660/4885GAA 2317/4885ALDH1A1 2797/4885 |
| US-20040220178-A1 | Substituted heterocycle fused gamma-carbolines | HCRTR1, HTR2C, OPRK1 | HTR2A 30/4885GAA 3686/4885ALDH1A1 704/4885 |
| US-20150157622-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER AND IMMUNOSUPPRESSION | MAVS, NDUFAF1, TFAM | HTR2A 2135/4885GAA 3846/4885ALDH1A1 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.